Cell No. : Cell Name
RCB5393 : S3D8_Spike
update : 2024/01/17
|
| Comment | |
| Comment from the depositor | This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S3D8). |
| Terms and conditions | 1)There is no restriction regarding use for basic researches. 2) The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. 3) In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (J Biol Chem 2021 296:100346) designated by the DEPOSITOR is required.
|
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
MURANO, Kensaku
|
| Originator |
MURANO, Kensaku
|
| Year of deposit |
2021
|
| Cloning (depositor) |
Yes
|
| _Date (depositor) |
2020.06
|
| _Method (depositor) |
limiting dilution
|
| Animal |
_mouse x mouse
< Hybrid
|
| Classification |
hybrid cells
|
|
Lifespan |
infinite
|
| Morphology |
lymphocyte-like
|
| Cellosaurus(Expasy) |
CVCL_A7AH
|
|
hybridoma
|
Fusion_cell_1 name |
SP2/0-Ag14 (RCB0209)
|
| Fusion_cell_1 strain |
mouse, BALB/c
|
| Fusion_cell_2 name |
spleen
|
| Fusion_cell_2 strain |
mouse, Balb/c
|
| Fusion_cell_2 gender |
Female
|
|
Fusion method |
electro cell fusion, HAT selection, ELISA
|
|
Antibody name |
S3D8
|
| Subclass |
IgG2a(Kappa)
|
| Immunogen |
spike glycoprotein (Expi293 Expression System)
|
|
Antigen_name |
SARS-CoV-2 Spike
|
| Antigen_m.w. |
200 kDa (SDS-PAGE)
|
| Antigen_character |
glycosylated protein
|
| Antigen_epitope |
RBD (receptor binding domain)
|
|
Antigen_positive |
SARS-CoV-2 infection to VeroE6/TMPRSS2 cells
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
Suspension cells
|
Suspension cells
|
| Culture medium |
Hybridoma Serum-Free Medium (FUJIFILM Wako #081-10381) + 1ng/mL IL-6 (Recombinant Human Interleukin-6, PeproTech #200-06)
|
Hybridoma Serum-Free Medium + 1ng/mL human IL-6
|
| Culture method |
|
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
| Designated culture dish |
non-coated dish, non-coated fask
|
|
Culture information
|
Passage cell No |
1-2×10 5 cells/mL
|
|
| Passage ratio |
|
1 : 10 split
|
| SC frequency |
Subculture : every day or every other day (< 1.0×10 6 cells/mL)
|
Subculture : 3 times/week
|
| Temperature |
37
℃
|
37
℃
|
| CO2 concentration |
5
%
|
5
%
|
| Freeze medium |
CELLBANKER 1 (Zenoaq #CB011)
|
CELLBANKER 1
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Antibody subclass |
|
IgG2a(Kappa)
|
| Saturation density |
1.5×10 6 cells/mL
|
|
| Doubling time |
15
hr
|
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
2
|
| User's Publication |
1
|
Back
Top
CELL BANK Website
